Company news
Psyence Biomedical Ltd. (NASDAQ:PBM) news
Psyence Biomedical Ltd. news releases on 6ix. Latest, Oct 5, 2026: Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S.…
Press releases & updates
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
October 4, 2026
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
September 28, 2026
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
May 15, 2026
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
April 23, 2026
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
April 19, 2026
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
April 17, 2026
Pacific Bay & Aurwest Sign Weaver Gold Property Definitive Option/JV Agreement
April 14, 2026
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
April 7, 2026
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
March 10, 2026
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
March 3, 2026
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
February 20, 2026
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
February 17, 2026
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
February 13, 2026
Psyence BioMed Announces Settlement of Shareholder Litigation
February 11, 2026
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
January 28, 2026
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
January 22, 2026
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
January 20, 2026
Psyence Biomedical : Interim Financials – September 30 2025
January 13, 2026
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
January 12, 2026
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
January 5, 2026
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
December 19, 2025
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
December 9, 2025
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
November 25, 2025
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
November 20, 2025
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
November 12, 2025
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care
November 6, 2025
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
November 3, 2025
Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
August 28, 2025
Corporate Update, August 2025
August 4, 2025
Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
July 31, 2025
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
June 24, 2025
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
June 18, 2025
PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares
June 17, 2025
Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements
June 17, 2025
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial
May 27, 2025
Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
May 1, 2025
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
April 17, 2025
Psyence Group Announces Share Consolidation
April 16, 2025
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
April 15, 2025
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia
April 8, 2025
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
March 31, 2025
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein
March 18, 2025
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
March 9, 2025
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
February 26, 2025
Psyence Biomedical : Biomed Announces $2.0 Million Private Placement Form 6 K
December 22, 2024
Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
December 22, 2024
Psyence Biomed Announces $2.0 Million Private Placement
December 22, 2024
Psyence Biomedical : Biomed Executes Binding Agreements with Optimi Health Corp Form 6 K
December 19, 2024
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
December 16, 2024
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
December 9, 2024